Who Owns H.I.V.-Prevention Drugs? The Taxpayers, U.S. Says

After years of prodding by patient advocates, federal officials on Wednesday sued the drug maker Gilead Sciences, charging that it had infringed government patents on the idea of preventing H.I.V. with a daily pill. The suit, by the Department of Health and Human Services, came as a pleasant shock to many critics of the company, including Democratic members of Congress […]

Read more

Intensive Anti-H.I.V. Efforts Meet With Mixed Success in Africa

Imagine that 90 percent of all people living with H.I.V. were diagnosed and treated with drugs. Would that be sufficient to end the AIDS epidemic? Scientists tried to answer the question in three enormous studies published on Wednesday in the New England Journal of Medicine. Instead of simply urging people to get testing and treatment for H.I.V., health workers in […]

Read more

Half of H.I.V. Patients Are Women. Most Research Subjects Are Men.

Inspired by reports of a second patient apparently freed of infection with H.I.V., the virus that causes AIDS, scientists are pursuing dozens of ways to cure the disease. But now, researchers must reckon with a longstanding obstacle: the lack of women in clinical trials of potential H.I.V. treatments, cures and vaccines. Women make up just over half of the 35 […]

Read more

Gilead Will Donate Truvada to U.S. for H.I.V. Prevention

Gilead Sciences, maker of Truvada, the only drug approved to prevent infection with H.I.V., will donate enough of the drug to supply 200,000 patients annually for up to 11 years, federal health officials announced on Thursday. Officials at the Department of Health and Human Services said the donation came about “as a result of discussions between the Trump administration and […]

Read more

Scientists Are Gaining Ground Against AIDS

The unnamed “London patient” — the second person apparently cured of H.I.V. — earned all the headlines. But other research released this week at the Conference on Retroviruses and Opportunistic Infections showed that scientists are making slow but steady progress on the tactics and medicines needed to fight the epidemic, especially in Africa. Monthly injections of long-acting H.I.V. drugs proved […]

Read more